Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Langer

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Journal of Neuroendocrinology|March 26, 2021
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasmsHans-Christian Pommergaard, Kirstine Nielsen, Halfdan Sorbye, et al.
Neuroendocrinology|October 1, 2020
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical CorrelationsHege Elvebakken, Aurel Perren, Jean-Yves Scoazec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC studyH Sorbye, S Welin, S W Langer, et al.
British Journal of Cancer|July 14, 2025
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 studyHalfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, et al.
International Journal of Cancer|February 5, 2026
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomasSiren Morken, Seppo W Langer, Geir Olav Hjortland, et al.
British Journal of Cancer|May 17, 2025
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 studyHalfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
Cancers|October 13, 2021
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World EfficacyMette T Mouritzen, Andreas Carus, Morten Ladekarl, et al.
Acta Oncologica (Stockholm, Sweden)|January 11, 2022
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world studyMette T Mouritzen, Karen F Junker, Andreas Carus, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Journal of Neuroendocrinology|March 26, 2021
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasmsHans-Christian Pommergaard, Kirstine Nielsen, Halfdan Sorbye, et al.
Neuroendocrinology|October 1, 2020
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical CorrelationsHege Elvebakken, Aurel Perren, Jean-Yves Scoazec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC studyH Sorbye, S Welin, S W Langer, et al.
British Journal of Cancer|July 14, 2025
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 studyHalfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, et al.
International Journal of Cancer|February 5, 2026
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomasSiren Morken, Seppo W Langer, Geir Olav Hjortland, et al.
British Journal of Cancer|May 17, 2025
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 studyHalfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
Cancers|October 13, 2021
Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World EfficacyMette T Mouritzen, Andreas Carus, Morten Ladekarl, et al.
Acta Oncologica (Stockholm, Sweden)|January 11, 2022
Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world studyMette T Mouritzen, Karen F Junker, Andreas Carus, et al.
Pageof 20